Effective Treatment of Persistent Grover's Disease with Trichloroacetic Acid Peeling

Abstract

have indicated no significant interest with commercial supporters.

Successful treatment of hypertrophic lichen planus with betamethasone under occlusion and TCA-peelings

“…genital warts), or acanthosis nigricans . There are only anecdotal cases of use of TCA‐containing solutions for the treatment of inflammatory cutaneous diseases (e.g., Grover's disease) .…”

Comment on “Grover disease: review of subtypes with a focus on management options”

“…6In summary, treatment options for GD include topical emollients (e.g., 10% glycerin in sorbolene cream), mercurochrome solution, salicylic acid or urea-containing ointments, zinc oxide cream, mentholated lotions, topical steroids, topical retinoids, topical vitamin D analogues (calcitriol, calcipotriol, or tacalcitol ointment), triple antibiotic ointment, 40% TCA, oral antihistamines (hydroxyzine, cetirizine, and fexofenadine), nbUVB, bath PUVA, oral PUVA with methoxsalen, ultraviolet A1, oral prednisone, oral retinoids (acitretin and isotretinoin), photodynamic therapy with topical 5-aminolevulinic acid (5-ALA), total skin electron beam radiotherapy, Grenz irradiation, methotrexate, and etanercept. [1][2][3][4][5][6] We would like to thank Aldana and Khachemoune for their extensive review on GD and would like to encourage physicians to perform prospective studies on GD. The development of a patient registry for GD would also be helpful in order to elucidate the most effective treatment options in patients with GD.…”

“…A very gentle application of 1.5 mL of 40% TCA was applied, and the procedure is described in detail within this article. 4 In another case report, total skin electron beam radiotherapy was used to treat recalcitrant GD. 5 proliferation that produces IL-17, a proinflammatory cytokine linked to the pathogenesis of several autoimmune conditions.…”

“…5 proliferation that produces IL-17, a proinflammatory cytokine linked to the pathogenesis of several autoimmune conditions. 3,4 Janus kinase (JAK) 2 has also been demonstrated to be an intracellular mediator of IL-23 cell surface receptor binding. 3 Recent evidence supports the role of IL-17 in the pathogenesis of AA, highlighting the potential therapeutic role by targeting IL-23.…”

“…3 Recent evidence supports the role of IL-17 in the pathogenesis of AA, highlighting the potential therapeutic role by targeting IL-23. 4 To study the efficacy of tildrakizumab in chronic AA,…”